IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue

Mucosal Immunology

Volumn 7, Issue 1, 2014, Pages 124-133

  Leung, J M ^a   Davenport, M ^a   Wolff, M J ^a,b   Wiens, K E ^a   Abidi, W M ^c   Poles, M A ^a,b   Cho, I ^a,b   Ullman, T ^c   Mayer, L ^c   Loke, P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 22; TRANSCRIPTION FACTOR C MAF; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLOSTRIDIALES; COLITIS; COLON FLORA; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; LAMINA PROPRIA; LYMPHOCYTE DEPLETION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOBACTERIA; TH17 CELL; TH22 CELL; ULCERATIVE COLITIS;

CD4-POSITIVE T-LYMPHOCYTES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MICROBIOTA; T-LYMPHOCYTE SUBSETS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84890897895     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.31     Document Type: Article

References (40)

1. Strober, W. & Fuss, I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140, 1756-1767 (2011).
2. Kaser, A., Zeissig, S. & Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010).
3. Mayer, L. Evolving paradigms in the pathogenesis of IBD. J. Gastroenterol. 45, 9-16 (2010).
4. Maloy, K.J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298-306 (2011).
5. Littman,D.R. & Rudensky, A.Y. Th17 and regulatory Tcells inmediating and restraining inflammation. Cell 140, 845-858 (2010).
6. Brand, S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167 (2009).
7. Trifari, S. & Spits, H. IL-22-producing CD4+ Tcells: middle-men between the immune system and its environment. Eur. J. Immunol 40, 2369-2371 (2010).
8. Ouyang, W., Kolls, J.K. & Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454-467 (2008).
9. Sonnenberg, G.F., Fouser, L.A. & Artis, D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383-390 (2011).
10. Spits, H. & Di Santo, J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12, 21-27 (2011).
11. Colonna, M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31, 15-23 (2009).
12. Broadhurst, M.J. et al. IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci. Transl. Med. 2, 60ra88 (2010).
13. Achyut, B.R. & Yang, L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 141, 1167-1178 (2011).
14. Rutz, S. et al. Transcription factor c-Maf mediates the TGF-betadependent suppression of IL-22 production in T(H)17 cells. Nat. Immunol. 12, 1238-1245 (2011).
15. Abraham, C. & Cho, J.H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066-2078 (2009).
16. Lepage, P. et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141, 227-236 (2011).
17. Geboes, K. & De Hertogh, G. Indeterminate colitis. Inflamm. Bowel Dis. 9, 324-331 (2003).
18. Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A. & Sallusto, F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol 10, 857-863 (2009).
19. Volpe, E. et al. Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production. Blood 114, 3610-3614 (2009).
20. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282-289 (2008).
21. Aujla, S.J. et al. IL-22 mediates mucosal host defense against Gramnegative bacterial pneumonia. Nat. Med. 14, 275-281 (2008).
22. Abraham, C. & Medzhitov, R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140, 1729-1737 (2011).
23. Caporaso, J.G. et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 6, 1621-1624 (2012).
24. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
25. Kim, C.J. et al. A role for mucosal IL-22 production and Th22 cells in HIVassociated mucosal immunopathogenesis. Mucosal Immunol. 5, 670-680 (2012).
26. Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465-1472 (2009).
27. Sugimoto, K. et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534-544 (2008).
28. Zenewicz, L.A., Yancopoulos, G.D., Valenzuela, D.M., Murphy, A.J., Stevens, S. & Flavell, R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29, 947-957 (2008).
29. Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127-1133 (2011).
30. Sekikawa, A. et al. Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. Lab. Invest. 90, 496-505 (2010).
31. Trifari, S.,Kaplan,C.D., Tran, E.H.,Crellin, N.K. &Spits, H. Identification of a human helper Tcell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10, 864-871 (2009).
32. Basu, R. et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 37, 1061-1075 (2012).
33. Rifkin, D.B. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J. Biol. Chem. 280, 7409-7412 (2005).
34. Monteleone, G., Boirivant, M., Pallone, F. & MacDonald, T.T. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol. 1 (Suppl 1), S50- S53 (2008).
35. Clemente, J.C., Ursell, L.K., Parfrey, L.W. & Knight, R. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258-1270 (2012).
36. Cho, I. & Blaser,M.J. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260-270 (2012).
37. Caporaso, J.G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc. Natl. Acad. Sci. USA 108 (Suppl 1), 4516-4522 (2011).
38. Caporaso, J.G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335-336 (2010).
39. Goecks, J., Nekrutenko, A. & Taylor, J. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 11, R86 (2010).
40. Blankenberg, D. et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr. Protoc.Mol.Biol.Chapter19:Unit 19.10)1-21 (2010).